1. Home
  2. MXCT vs LOKV Comparison

MXCT vs LOKV Comparison

Compare MXCT & LOKV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MXCT
  • LOKV
  • Stock Information
  • Founded
  • MXCT 1999
  • LOKV 2024
  • Country
  • MXCT United States
  • LOKV United States
  • Employees
  • MXCT N/A
  • LOKV N/A
  • Industry
  • MXCT Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • LOKV
  • Sector
  • MXCT Health Care
  • LOKV
  • Exchange
  • MXCT Nasdaq
  • LOKV Nasdaq
  • Market Cap
  • MXCT 275.7M
  • LOKV 288.1M
  • IPO Year
  • MXCT 2021
  • LOKV 2025
  • Fundamental
  • Price
  • MXCT $2.21
  • LOKV $10.05
  • Analyst Decision
  • MXCT Strong Buy
  • LOKV
  • Analyst Count
  • MXCT 1
  • LOKV 0
  • Target Price
  • MXCT $9.00
  • LOKV N/A
  • AVG Volume (30 Days)
  • MXCT 811.6K
  • LOKV 2.3K
  • Earning Date
  • MXCT 05-07-2025
  • LOKV 01-01-0001
  • Dividend Yield
  • MXCT N/A
  • LOKV N/A
  • EPS Growth
  • MXCT N/A
  • LOKV N/A
  • EPS
  • MXCT N/A
  • LOKV N/A
  • Revenue
  • MXCT $37,675,000.00
  • LOKV N/A
  • Revenue This Year
  • MXCT $9.05
  • LOKV N/A
  • Revenue Next Year
  • MXCT $19.98
  • LOKV N/A
  • P/E Ratio
  • MXCT N/A
  • LOKV N/A
  • Revenue Growth
  • MXCT N/A
  • LOKV N/A
  • 52 Week Low
  • MXCT $2.21
  • LOKV $9.80
  • 52 Week High
  • MXCT $5.26
  • LOKV $10.25
  • Technical
  • Relative Strength Index (RSI)
  • MXCT 31.54
  • LOKV N/A
  • Support Level
  • MXCT $2.60
  • LOKV N/A
  • Resistance Level
  • MXCT $2.86
  • LOKV N/A
  • Average True Range (ATR)
  • MXCT 0.15
  • LOKV 0.00
  • MACD
  • MXCT -0.03
  • LOKV 0.00
  • Stochastic Oscillator
  • MXCT 5.43
  • LOKV 0.00

About MXCT MaxCyte Inc.

MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.

About LOKV Live Oak Acquisition Corp. V Class A Ordinary Shares

Live Oak Acquisition Corp V is a blank check company.

Share on Social Networks: